- |||||||||| benufutamab (GEN1029) / Genmab
Enrollment change, Trial completion date, Trial termination: GEN1029 (HexaBody (clinicaltrials.gov) - Jan 11, 2022
P1/2, N=48, Terminated,
N=520 --> 48 | Trial completion date: Mar 2022 --> Oct 2021 | Recruiting --> Terminated; Sponsor decision
- |||||||||| benufutamab (GEN1029) / Genmab, Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
Preclinical, Journal: Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. (Pubmed Central) - Jun 1, 2021
Daratumumab showed additive effects when combined with HexaBody-DR5/DR5. In conclusion, the results of this preclinical study indicate a therapeutic potential for HexaBody-DR5/DR5, especially in recently treated relapsed/refractory MM patients.
- |||||||||| benufutamab (GEN1029) / Genmab
Enrollment change: GEN1029 (HexaBody (clinicaltrials.gov) - Jan 13, 2020
P1/2, N=520, Recruiting,
In conclusion, the results of this preclinical study indicate a therapeutic potential for HexaBody-DR5/DR5, especially in recently treated relapsed/refractory MM patients. N=188 --> 520
- |||||||||| GEN1029 / Genmab
HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models (Board 25: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_458;
P1/2
A Phase 1/2 clinical trial to determine the RP2D and assess clinical safety of HexaBody-DR5/DR5 in cancer patients is currently ongoing (NCT03576131), from which a case study will be presented. Conclusion Potent anti-tumor activity of HexaBody-DR5/DR5 was observed in large and diverse panels of CRC, gastric and urothelial PDX models, providing preclinical rationale for the clinical evaluation of HexaBody-DR5/DR5 in these indications.
- |||||||||| benufutamab (GEN1029) / Genmab
New P1/2 trial: GEN1029 (HexaBody (clinicaltrials.gov) - Jul 15, 2018
P1/2, N=188, Recruiting,
|
